Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any gender
• People who have been diagnosed with locally advanced or metastatic esophageal cancer or lung cancer, confirmed through a tissue or cell sample, and have not yet received treatment for it
• People who have never previously received chemotherapy drugs for cancer treatment
• People whose treatment plan includes at least 4 cycles of chemotherapy combined with immunotherapy, using cisplatin or carboplatin
• People whose doctors expect them to live for at least 3 months or more
• People who are generally able to carry out normal daily activities with little or no limitation (based on a standard medical scoring system called ECOG, scoring 0 or 1)
• People whose blood counts and organ function meet specific health thresholds, including healthy levels of white blood cells, red blood cells, and platelets; liver, kidney, and heart function within acceptable ranges; and a normal heart rhythm on an ECG (confirm with trial site)
• People who are able and willing to use effective contraception from the time of signing the consent form until 6 months after the last dose — this applies to women who are able to become pregnant, and to men whose partners are able to become pregnant
• Women who are able to become pregnant must have a negative blood pregnancy test within 72 hours before being enrolled, and must not be breastfeeding
• People who clearly understand the study and voluntarily agree to participate by signing a consent form

Who may not be able to join:

• People who received radiation therapy to the abdomen or pelvis within 7 days before enrolment, or who plan to receive it within the first 8 days of treatment
• People whose treatment plan includes chemotherapy drugs carrying a high risk of causing vomiting in the days following their platinum-based treatment
• People whose chemotherapy plan includes a specific form of paclitaxel that uses castor oil as its base ingredient
• People who have taken certain anti-nausea or related medications within 2 days before enrolment, including certain common anti-nausea drugs, antipsychotics, stomach-motility drugs, or herbal medicines with anti-nausea effects (confirm with trial site for the full list)
• People who have started taking benzodiazepine or opioid medications within 2 days before enrolment, with some specific exceptions (confirm with trial site)
• People who started taking morphine within 7 days before enrolment, unless they have been on a stable dose for that period
• People who received steroid medications (such as dexamethasone or prednisolone) or sedating antihistamines (such as diphenhydramine) within 7 days before enrolment, with limited exceptions (confirm with trial site)
• People who used a medication called palonosetron within 14 days before enrolment
• People who used a type of medication called an NK-1 receptor antagonist within 28 days before enrolment
• People who used certain specific medications that interact with liver enzymes (CYP3A4 or CYP2D6) within 7 to 28 days before enrolment, depending on the medication (confirm with trial site for specific drug names)
• People who experienced vomiting, retching, or nausea in the 24 hours before enrolment
• People who have brain metastases causing symptoms
• People with uncontrolled fluid build-up in body cavities such as the lungs, abdomen, or around the heart — unless it has been treated and stable for at least 2 weeks
• People who have had a serious heart condition within the 3 months before enrolment, such as a heart attack, unstable chest pain, significant heart valve disease, or heart failure
• People with poorly controlled high blood pressure before enrolment (two consecutive resting readings at or above 160/100 mmHg)
• People with active hepatitis B, active hepatitis C, HIV/AIDS, or syphilis
• People with other health conditions that would prevent them from safely taking dexamethasone, such as active infections or uncontrolled illnesses like poorly controlled diabetes
• People with known allergies or contraindications to NK-1 receptor antagonists, 5-HT3 receptor antagonists, or dexamethasone
• People who have taken part in another clinical trial within 30 days before enrolment
• People whom the trial investigators consider unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.